Still emerging from infancy, the developing field of trauma theory called “moral injury” (MI) has opened fresh vistas for biblical studies. Scholars are now beginning to employ MI theory as an interpretive frame of reference to biblical scenes depicting high intensity scenarios where moral values are challenged. Surprisingly, engagement of MI theory to the Fourth Gospel has yet to be done despite its specified portrayal of individual scenes of mental suffering. Attempting to fill the void, this article examines and appropriates recent MI research to propose a fresh reading of a significant, yet often overlooked, Johannine narrative of trauma: the βασιλικός (“royal official”) of John 4:46–54. Perhaps plagued by parental guilt over his dying son and tensions caused by a career forcing him to hold in balance conflicting Jewish and gentile sensibilities, the article engages insights borrowed from MI theory, posing a horizontal reading of the text that sheds light on this father’s inner trauma. In doing so, it invites similar sufferers today to rely on the Jesus in whom the βασιλικός sought relief.
BACKGROUND:The microbiologic etiologies, clinical manifestations, and antimicrobial treatment of neonatal infections differ substantially from infections in adult and pediatric patient populations. In 2019, the Centers for Disease Control and Prevention developed neonatal-specific (Standardized Antimicrobial Administration Ratios SAARs), a set of risk-adjusted antimicrobial use metrics that hospitals participating in the National Healthcare Safety Network's (NHSN's) antimicrobial use surveillance can use in their antibiotic stewardship programs (ASPs).METHODS:The Centers for Disease Control and Prevention, in collaboration with the Vermont Oxford Network, identified eligible patient care locations, defined SAAR agent categories, and implemented neonatal-specific NHSN Annual Hospital Survey questions to gather hospital-level data necessary for risk adjustment. SAAR predictive models were developed using 2018 data reported to NHSN from eligible neonatal units.RESULTS:The 2018 baseline neonatal SAAR models were developed for 7 SAAR antimicrobial agent categories using data reported from 324 neonatal units in 304 unique hospitals. Final models were used to calculate predicted antimicrobial days, the SAAR denominator, for level II neonatal special care nurseries and level II/III, III, and IV NICUs.CONCLUSIONS:NHSN's initial set of neonatal SAARs provides a way for hospital ASPs to assess whether antimicrobial agents in their facility are used at significantly higher or lower rates compared with a national baseline or whether an individual SAAR value is above or below a specific percentile on a given SAAR distribution, which can prompt investigations into prescribing practices and inform ASP interventions.
Updated several times a week with posts by a wide variety of authors, AJN's blog Off the Charts allows us to provide more timely-and often more personal-perspectives on professional, policy, and clinical issues. Best of the Blog is a regular column to draw the attention of AJN readers to posts we think deserve a wider audience. To read more, please visit: www.ajnoffthecharts.com.